Colibris Canna Consulting & Coaching

Call Directions Website Contact the business

Colibris Canna Consulting & Coaching Certified Medical Cannabis Nurse & Dual board-certified Integrative Holistic Nurse Coach

https://www.facebook.com/share/19L1KkWW3W/?mibextid=wwXIfr
10/30/2026

https://www.facebook.com/share/19L1KkWW3W/?mibextid=wwXIfr

A medication commonly found in pharmacies for treating diarrhea may have an unexpected effect on one of the deadliest forms of brain cancer. Glioblastoma is an aggressive brain tumor known for its rapid growth, resistance to treatment, and high recurrence rates.

A 2021 study published in the journal Autophagy investigated whether loperamide, an over-the-counter anti-diarrheal drug, and pimozide, an antipsychotic medication, could trigger cell death in human glioblastoma cells. Researchers at Goethe University Frankfurt studied MZ-54 glioblastoma cells and discovered that both medications induced a form of cell death dependent on autophagy, the process cells use to break down and recycle damaged components. Rather than simply blocking cancer cell growth, the drugs disrupted several cellular survival mechanisms simultaneously.

Specifically, loperamide and pimozide caused substantial accumulation of cholesterol and other lipids inside lysosomes, the structures responsible for cellular waste processing. Researchers also observed increased levels of ceramides, glucosylceramides, and sphingoid bases, alongside inhibition of acid sphingomyelinase (SMPD1/ASM), an enzyme involved in lipid metabolism.

These changes contributed to lysosomal membrane permeabilization, allowing enzymes such as cathepsin B to escape into the cytoplasm and promote cancer cell death. Importantly, when researchers knocked out the autophagy-related genes ATG5 and ATG7, both lysosomal damage and cell death were significantly reduced. Cathepsin inhibitors and the antioxidant alpha-tocopherol (vitamin E) also reduced cell death, suggesting that lysosomal enzymes and lipid-related oxidative damage contributed to the effects.

These findings identify a potential strategy for targeting glioblastoma through excessive autophagy and lysosomal disruption.

https://www.facebook.com/share/p/1EzYUSjjg8/?mibextid=wwXIfr&direct_share_include_copy=1&fb_entity_type=newsfeed
10/01/2026

https://www.facebook.com/share/p/1EzYUSjjg8/?mibextid=wwXIfr&direct_share_include_copy=1&fb_entity_type=newsfeed

A 2026 study in Nature Communications tested a new mRNA based immunotherapy approach for pancreatic ductal adenocarcinoma, a form of pancreatic cancer that is very difficult to treat.

The research paper is titled “Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer.” It is linked to PMID 42321218 and DOI 10.1038/s41467-026-74574-z.

Researchers at UMass Chan Medical School designed the treatment to change the tumor environment around pancreatic cancer. These tumors often block immune cells and lack the right signals needed for a strong immune attack.

The team used mRNAs that encode five immune signaling molecules, also called cytokines. These were combined with mRNAs that encode tumor associated antigens, so the immune system could both become activated and learn what to target.

In mouse models, the cytokine mRNA mix activated natural killer cells and CD8 positive T cells. It also reduced tumor growth and fibrosis, which is the dense scar like tissue that can help pancreatic tumors resist treatment.

The researchers then added tumor antigen mRNAs to strengthen cancer specific T cell responses. The combined treatment was delivered systemically using lipid nanoparticles.

In genetically engineered mouse models of pancreatic cancer, the lipid nanoparticles helped direct immune activity toward pancreatic tumors. The most notable result came from autochthonous pancreatic cancer models, where complete tumor responses occurred in about 50 percent of treated animals.

The study also found signs of durable immune memory. Antigen reactive T cells persisted after treatment, and some animals remained protected long term after therapy stopped.

This is an important preclinical finding, but it does not mean pancreatic cancer has been cured in humans. The work was done in animal models, and human clinical trials are still needed to test safety and effectiveness in people.

https://www.science.org/doi/10.1126/science.aec6116?fbclid=IwZnRzaAUQEtVwZG9mBWZkaWQWUOLAWRcc9G2-1DoOaE-1zTBuFQBk9GV4dG4...
09/10/2026

https://www.science.org/doi/10.1126/science.aec6116?fbclid=IwZnRzaAUQEtVwZG9mBWZkaWQWUOLAWRcc9G2-1DoOaE-1zTBuFQBk9GV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR7oJf5M50oNd2LF88VjQdI7aBazz2hOJ2Heuo-45ZbmlCXyyG0zwozRrGZcCQ_aem_w6Qhs4NAJFnZHpFUZjzmnw

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling, often irreversible toxicity that affects millions of patients, limits life-saving cancer therapy, and lacks proven treatment. In this work, we show that as little as two doses of ...

05/20/2025

Recent advances in cancer research have unveiled innovative strategies that cause cancer cells to destroy themselves. At Penn State University, scientists have developed a modular genetic circuit that turns cancer cells into “Trojan horses,” reprogramming them to initiate their own death while also eliminating surrounding drug-resistant cells. This technique has delivered promising results in lab-grown human cells and mouse models, offering a potential breakthrough in tackling cancer’s complexity and resistance to standard treatments.

Meanwhile, another team of researchers has designed a cutting-edge molecule to fight blood cancer by targeting the BCL6 protein—a key player in helping cancer cells evade death. By linking BCL6 with the BRD4 protein, this new compound reactivates suppressed cell death signals, triggering the cancer cells to self-destruct. This development introduces a powerful new class of cancer therapies with broad potential across various types of cancer.

Low-doses of THC, C*D, & CBG. . .
01/27/2025

Low-doses of THC, C*D, & CBG. . .

A study by the University of the Basque Country (UPV/EHU) demonstrates that the drug WIN55,212-2 protects the brain and reverses early cognitive damage caused by dementia, while also explaining its mechanism of action. Over two decades of research conducted by the Neurochemistry and Neurodegenera

Address

35 Slide Rock Road
Sedona, AZ
86351

Alerts

Be the first to know and let us send you an email when Colibris Canna Consulting & Coaching posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Colibris Canna Consulting & Coaching:

Shortcuts

Share

Nearby health & beauty businesses